Cargando…

Reply to: “Malignant transformation of hepatocellular adenoma”

Detalles Bibliográficos
Autores principales:	Chopinet, Sophie, Beaufrère, Aurélie, Soubrane, Olivier, Cauchy, François, Paradis, Valérie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810563/ https://www.ncbi.nlm.nih.gov/pubmed/35141512 http://dx.doi.org/10.1016/j.jhepr.2022.100429

Ejemplares similares

Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas
por: Chopinet, Sophie, et al.
Publicado: (2021)

Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI
por: Michallek, Florian, et al.
Publicado: (2022)

Malignant transformation of hepatocellular adenoma
por: Julien, Céline, et al.
Publicado: (2022)

Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS
por: Cannella, Roberto, et al.
Publicado: (2021)

Colorectal liver metastases: radiopathological correlation
por: Paulatto, Luisa, et al.
Publicado: (2020)

New insights into the pathophysiology and clinical care of rare primary liver cancers
por: Gigante, Elia, et al.
Publicado: (2020)

The authors reply
por: Thaunat, Olivier, et al.
Publicado: (2021)

Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome
por: Laouirem, Samira, et al.
Publicado: (2018)

Malignant transformation of hepatocellular adenoma: report of a case
por: Mouhoub, Mohamed, et al.
Publicado: (2020)

Reply: The performance of the risk of ovarian malignancy algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Malignant Transformation of an HNF1a-Inactivated Hepatocellular Adenoma to Hepatocellular Carcinoma
por: Hepkema, Joris T., et al.
Publicado: (2020)

National survey of invasive procedural training for nephrology fellows and residents in France: from bedside mentoring to simulation-based teaching
por: Bobot, Mickaël, et al.
Publicado: (2020)

Reply: Faecal tumour pyruvate kinase M2: not a good marker for detection of colorectal adenomas
por: Haug, U, et al.
Publicado: (2008)

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
por: Bouattour, Mohamed, et al.
Publicado: (2016)

Reply to ‘Malignant pericardial effusion: sclerotherapy or local chemotherapy?’
por: Kunitoh, H, et al.
Publicado: (2009)

LATE SURGICAL TREATMENT FOR SPONTANEOUS RUPTURE OF HEPATOCELLULAR ADENOMA: CASE REPORT
por: PINTO, Luis Eduardo Veras, et al.
Publicado: (2015)

Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers
por: An, Song-Lin, et al.
Publicado: (2015)

The authors reply
por: Hazzan, Marc, et al.
Publicado: (2020)

The Authors Reply
por: Duval, Anna, et al.
Publicado: (2019)

Reply: A morpho-molecular prognostic model for hepatocellular carcinoma
por: Srivastava, S, et al.
Publicado: (2013)

MALDI Imaging, a Powerful Multiplex Approach to Decipher Intratumoral Heterogeneity: Combined Hepato-Cholangiocarcinomas as Proof of Concept
por: Gigante, Elia, et al.
Publicado: (2023)

Dynamic changes in DNA methylation and hydroxymethylation revealed the transformation of advanced adenoma into colorectal carcinoma
por: Dang, Yanqi, et al.
Publicado: (2023)

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
por: Osanto, Susanne, et al.
Publicado: (2022)

Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma
por: Souhami, Alexandra, et al.
Publicado: (2020)

The complexity of immune cell landscape in hepatocellular carcinomas with different risks—reply letter
por: Tang, Xiaofeng, et al.
Publicado: (2020)

Reply: Imaging-Based Obesity Assessment for Risk Factor Stratification and Prognostication in Malignancy
por: Liu, Elizabeth E., et al.
Publicado: (2022)

Reply to: The diagnostic accuracy of (18)F-FDG PET in cutaneous malignant melanoma
por: Delgado-Bolton, Roberto C., et al.
Publicado: (2010)

Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy - reply: Reply to the letter from Benson and Colletta
por: MacCallum, J, et al.
Publicado: (1997)

Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis
por: Thevathasan, Tharusan, et al.
Publicado: (2021)

An update of oral potentially malignant disorders and their malignant transformation into oral cancers in Taiwan
por: Yang, Po-Yu, et al.
Publicado: (2021)

Reply to: Comment on ‘Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area'
por: Sideras, Kostandinos, et al.
Publicado: (2016)

Reply to ‘Comment on ‘Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion’ ’
por: Waked, Iman, et al.
Publicado: (2017)

Reply to: “Reconsidering low HDL-cholesterol levels as a predictive factor for the development of hepatocellular carcinoma”
por: Crudele, Lucilla, et al.
Publicado: (2023)

Reply
por: Israelsen, Simone Bastrup, et al.
Publicado: (2022)

Reply
por: Giubilini, Alberto, et al.
Publicado: (2022)

Reply
por: Pettoello-Mantovani, Massimo, et al.
Publicado: (2022)

Reply
por: Minocha, Prashant K., et al.
Publicado: (2022)

In Reply
por: Von Hoff, Daniel, et al.
Publicado: (2022)

Reply
por: Wang, Jitao, et al.
Publicado: (2022)

Reply
por: Andraska, Elizabeth A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g9lqr5t50tgebj5tvo38mc1ogt